Company intelligence / Profile preview
Arcellx
Redwood City, California, United Statesarcellx.com ↗
- Ownership
- Public · ACLX
- Development stage
- Other
01
Overview
Arcellx's lead candidate anitocabtagene autoleucel (anito-cel) has shown promising results in multiple myeloma with a 97% overall response rate and 62% complete response rate at a median follow-up of 9.5 months in the pivotal iMMagine-1 study. The Phase 1 study demonstrated durable benefit with a 30.2 month median progression-free survival. The safety profile has been manageable with no delayed neurotoxicities in 155 patients across Phase 1 and iMMagine-1 studies.
- Therapeutic areas
- OncologyNeurologyHematology
- Modalities
- Cell therapyCAR-T therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Kite, a Gilead Company
Beyond the preview
Go deeper on Arcellx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arcellx.